Display options
Cite
Jutras G, Bélanger K, Letarte N, et al. Procarbazine, lomustine and vincristine toxicity in low-grade gliomas. Curr Oncol. 2018;25(1):e33-e39doi: 10.3747/co.25.3680.
Jutras, G., Bélanger, K., Letarte, N., Adam, J. P., Roberge, D., Lemieux, B., Lemieux-Blanchard, �. �., Masucci, L., Ménard, C., Bahary, J. P., Moumdjian, R., Berthelet, F., & Florescu, M. (2018). Procarbazine, lomustine and vincristine toxicity in low-grade gliomas. Current oncology (Toronto, Ont.), 25(1), e33-e39. https://doi.org/10.3747/co.25.3680
Jutras, G, et al. "Procarbazine, lomustine and vincristine toxicity in low-grade gliomas." Current oncology (Toronto, Ont.) vol. 25,1 (2018): e33-e39. doi: https://doi.org/10.3747/co.25.3680
Jutras G, Bélanger K, Letarte N, Adam JP, Roberge D, Lemieux B, Lemieux-Blanchard É, Masucci L, Ménard C, Bahary JP, Moumdjian R, Berthelet F, Florescu M. Procarbazine, lomustine and vincristine toxicity in low-grade gliomas. Curr Oncol. 2018 Feb;25(1):e33-e39. doi: 10.3747/co.25.3680. Epub 2018 Feb 28. PMID: 29507493; PMCID: PMC5832288.
Copy Download .nbib Format: NLM
Share it on

Curr Oncol. 2018 Feb;25(1):e33-e39. doi: 10.3747/co.25.3680. Epub 2018 Feb 28.

Procarbazine, lomustine and vincristine toxicity in low-grade gliomas.

Current oncology (Toronto, Ont.)

G Jutras, K Bélanger, N Letarte, J-P Adam, D Roberge, B Lemieux, É Lemieux-Blanchard, L Masucci, C Ménard, J P Bahary, R Moumdjian, F Berthelet, M Florescu

Affiliations

  1. Faculty of Medicine, Université de Montréal, Montréal, QC.
  2. Centre hospitalier de l'Université de Montréal, Notre-Dame Hospital, Montréal, QC.
  3. Faculty of Pharmacy, University of Montreal, Montreal, QC; and.
  4. Department of Pharmacy at chum, Montréal, QC.

PMID: 29507493 PMCID: PMC5832288 DOI: 10.3747/co.25.3680

Abstract

BACKGROUND: Procarbazine, lomustine, and vincristine (pcv) significantly improve survival outcomes in lgg (low-grade gliomas). Administration of pcv to lgg patients increased tremendously over the past years as it went from 2 patients per year between 2005 and 2012 to 23 patients in 2015 only in our centre. However, serious hematological and non-hematological adverse events may occur. The purpose of this study was to evaluate the toxicity of pcv and its clinical relevance in our practice.

METHODS: We retrospectively reviewed the charts of 57 patients with lgg who received pcv at the Centre hospitalier de l'Université de Montréal between 1 January 2005 and 27 July 2016.

RESULTS: Procarbazine, lomustine, and vincristine were associated with severe hematological toxicity as clinically significant grade 3 anemia, neutropenia, and thrombocytopenia occurred in 7%, 10%, and 28% of patients, respectively. Other frequent adverse events such as the increase of liver enzymes, cutaneous rash, neurotoxicity, and vomiting occurred in 65%, 26%, 60%, and 40% of patients, respectively. Patients with prophylactic trimethoprim/sulfamethoxazole had more grade 3 hematological toxicity with pcv, especially anemia (

CONCLUSION: Procarbazine, lomustine, and vincristine increase survival in lgg but were also associated with major hematologic, hepatic, neurologic, and cutaneous toxicity. Anti-

Keywords: Chemotherapy; gliomas; toxicity

References

  1. Cancer. 1984 Nov 1;54(9):2006-8 - PubMed
  2. Curr Neurol Neurosci Rep. 2010 May;10(3):224-31 - PubMed
  3. J Clin Oncol. 2009 Sep 1;27(25):4150-4 - PubMed
  4. J Clin Oncol. 1997 Sep;15(9):3129-40 - PubMed
  5. J Clin Oncol. 2002 Apr 15;20(8):2076-84 - PubMed
  6. J Clin Oncol. 2003 Jan 15;21(2):251-5 - PubMed
  7. Rep Pract Oncol Radiother. 2012 Feb 10;17(3):141-5 - PubMed
  8. Neurology. 1998 Oct;51(4):1140-5 - PubMed
  9. Acta Neuropathol. 2007 Aug;114(2):97-109 - PubMed
  10. Scand J Haematol. 1980 Feb;24(2):149-51 - PubMed
  11. Oncologist. 2001;6(2):162-76 - PubMed
  12. CA Cancer J Clin. 2013 Nov-Dec;63(6):419-37 - PubMed
  13. N Engl J Med. 2016 Apr 7;374(14):1344-55 - PubMed
  14. Neurosurgery. 1998 Nov;43(5):1066-73 - PubMed
  15. Med Toxicol. 1986 Nov-Dec;1(6):421-7 - PubMed
  16. J Clin Oncol. 2006 Jun 20;24(18):2715-22 - PubMed
  17. J Allergy Clin Immunol. 1976 Feb;57(2):134-40 - PubMed
  18. Semin Oncol. 2003 Dec;30(6 Suppl 19):23-8 - PubMed
  19. J Neurosurg. 1996 Oct;85(4):602-7 - PubMed
  20. Oncologist. 2014 Apr;19(4):403-13 - PubMed
  21. Arch Intern Med. 2003 Feb 24;163(4):402-10 - PubMed

Publication Types